In contrast, IFN–β did not induce release (Fig. 1B) or production (Fig. 1C) of HGF by CD4+ T cells, an important source of other neurotrophic factors (e.g., brain-derived neurotrophic factor, BDNF) in MS patients during immunomodulatory drug therapy. This evidence concerns the gene IFNB1 and myeloid sarcoma.